Programming memory natural killer cells to defend the lungs against respiratory viruses with an mRNA vaccine

Original publication

Original publisher: The Conversation. The article outlines a government-funded Triumph-NK project at the University of Southampton that aims to end the burden of respiratory infections by memory programming natural killer cells in the nose and lungs, potentially offering broad protection across multiple viruses.

A concise explainer of the concept followed by key takeaways:

• Memory natural killer cells could act as gatekeepers in the nose and lungs, recognising a broad range of infected cells and slowing transmission of respiratory viruses.
• The Triumph-NK team plans to reprogram these cells in the body and deliver the stimuli via an mRNA vaccine platform similar to COVID vaccines.
• The approach targets innate immunity to provide rapid protection during outbreaks or pandemics, reducing delays inherent to virus-specific vaccines.
• Testing will span viruses such as influenza, RSV, and COVID-19, with a view toward an off-the-shelf, broad-spectrum respiratory vaccine.

Overview of Triumph-NK and its goals

Respiratory infections cause substantial global morbidity and mortality each year. The Triumph-NK project based at the University of Southampton seeks to prevent severe outcomes by programming memory natural killer (NK) cells to act as long-lived sentinels in the nose and lungs. By enhancing the innate immune response, the researchers aim to protect against a wide range of respiratory viruses and to deploy vaccines immediately in outbreaks or pandemics.

Natural killer cells and innate immunity

Natural killer cells are among the first responders to viral infection. Unlike the adaptive immune system, which is highly specific to a single virus or strain, NK cells can target cells infected by diverse viruses. Recent research has revealed that some NK cells persist as memory NK cells, residing in mucosal areas such as the nose and lungs. Triumph-NK’s core idea is to program these memory NK cells so that they can rapidly recognize and eliminate a broad spectrum of infected cells, thereby limiting viral spread from the initial sites of infection.

The research approach

To identify the most effective memory NK cell types for this job, researchers are performing DNA and RNA sequencing on NK cells from the nose and lungs. They are also mapping surface markers that distinguish memory NK cells. Once the right cell type and activation signals are identified, the team will test multiple stimuli in the laboratory. When they converge on a potent combination, they plan to deliver these stimuli using mRNA technology, leveraging the same platform used in COVID vaccines.

Vaccine design, testing, and timeline

The vaccine concept involves educating the body to generate memory NK cells that remain in place to defend the airways. Laboratory tests will evaluate robustness against a broad range of respiratory viruses, including influenza, COVID-19, and RSV. If successful, human studies could begin within five years, with the ultimate goal of a cost-effective, off-the-shelf vaccine suitable for vulnerable populations such as older adults and individuals with weakened immune systems. A key challenge will be translating laboratory protection to real-world human immunity, but a successful outcome could transform outbreak response by buying scientists time to develop targeted vaccines for emerging threats.

Context and potential impact

Triumph-NK sits within a broader programme called sustained viral resilience, which aims to strengthen the body's first line of defence. If memory NK cells can deliver broad, rapid protection in humans, this approach could complement or complementarily accelerate targeted vaccines during new virus emergence, potentially reducing severe disease and transmission in the earliest stages of outbreaks.